



Effective **January 1, 2023**, the following drugs will need to be billed to the Health Care Authority (HCA). For drugs that currently require prior authorization (PA), please submit PA requests to the HCA on or after January 1, 2023. For more information, please contact the HCA at 800-562-3022.

- Pyrimethamine (Daraprim)
- Pyrimethamine (Pyrimethamine)
- Teduglutide (RDNA) (Gattex)
- Pegloticase (Krystexxa)
- Eliglustat Tartrate (Cerdelga)
- Imiglucerase (Cerezyme)
- Taliglucerase Alfa (Elelyso)
- Miglustat (Miglustat)
- Velaglucerase Alfa (Vpriv)
- Miglustat (Zavesca)
- Pegzilarginase (AEB1102)
- Etranacogene Dezaparvovec (AMT-061)
- Lecanemab (BAN2401)
- Copper Histidinate (CUTX-101)
- Donanemab (Donanemab)
- Olipudase Alfa-RPCP (Xenpozyme)
- Olipudase Alfa (GZ402665)
- Bulevirtide (Myrcludex B)
- Omaveloxolone (Omax)
- Teplizumab (PRV-031)
- Vamorolone (VBP15)
- Efgartigimod Alfa-FCAB (Vyvgart)
- Sipuleucel-T (Provenge)
- Ibalizumab-Uiyk (Trogarzo)
- Enfuvirtide (Fuzeon)
- Zidovudine (Retrovir IV Infusion)
- Cabotegravir (Apretude)
- Cabotegravir & Rilpivirine (Cabenuva)